SENS & Underdog awarded $252,000 NIA research grant

Latest articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

It’s time to reboot longevity and healthy aging

Dr Michael Roizen calls for fundamental societal changes to ensure the benefits of longevity and healthy aging are realised. Later this year, best-selling author Michael...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Click the globe for translations.

SENS Research Foundation and Underdog Pharmaceuticals jointly awarded $252,000 NIA grant to eradicate atherosclerosis.

The National Institute on Aging (NIA) division of the National Institutes of Health (NIH) has awarded a grant to advance research on Engineered Cyclodextrins targeting toxic oxidised cholesterol to eradicate atherosclerosis — the cause of most heart attacks and strokes.

Former SRF VP of Research and current Underdog Co-founder Matthew O’Connor, PhD and current SRF VP of Research Alexandra Stolzing, PhD, are the Principal Investigators.

Longevity.Technology: Cardiovascular disease, heart attacks, and strokes are by far the world’s most life-threatening conditions, accounting for up to 40% of deaths in Europe and the US and with annual treatment costing more than £29 billion in the UK alone. The primary cause of these diseases and events is atherosclerosis, a build-up of plaque in the arterial walls.

Plaque forms when cholesterol lodges in the wall of the artery. Cholesterol comes from the liver – which is able to make all the cholesterol you need – and the food consumed by the body. Too much cholestorol and it builds up, sticking to artery walls and causing trouble. The body deploys white blood cells to alleviate the deposits, but they actually end up becoming foamy cells that causing more inflammation. Underdog’s engineered synthetic carbohydrate compounds are designed to target and remove toxic oxidised cholesterol, a key driver of arterial plaque accumulation.

Underdog Pharmaceuticals’ research has combined computational and synthetic chemistry programs to custom-engineer cyclodextrins to capture, and remove from cells, oxidised cholesterol derivatives such as 7-ketocholesterol. Their technology removes the arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.

The grant also supports exploring the use of Underdog’s technology to target oxidised cholesterol in the Alzheimer’s disease brain.

Their long-term goal is to deliver a simple and affordable preventive therapy for the world.

The novel therapeutic approach was born from one of SRF’s flagship research programmes designed to understand and repair the underlying causes of cardiovascular disease. In a press release, SENS Research Foundation and Underdog Pharmaceuticals said both organisations are very proud to receive this important peer-reviewed NIH grant.

“We are excited about how this collaboration will contribute to the advancement of our mission to develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging [1].”

[1] https://www.sens.org/sens-and-underdog-pharmaceuticals-jointly-awarded-nia-research-grant/

Photograph: Underdog Pharmaceuticals
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

Altos Labs lands $3 billion to further cellular rejuvenation programming

Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming. Altos Labs launched today as a new biotechnology company dedicated to unravelling...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

Cytosurge wins funding to address bottlenecks in neuroscience research

R&D project by Cytosurge and the Laboratory of Biosensors and Bioelectronics at the Swiss Federal Institute of Technology receives funding from Innosuisse. Cytosurge, a provider...

    Subscribe to our newsletter